KomFi. Academy

hard · CFA Level I Corporate Issuers

Amberfen Pharma is evaluating a research project with an initial outlay of 100 million. The project has a 4-year life. Depreciation is straight-line to zero over 4 years. The project is expected to generate annual revenues of $80 million and cash expenses of $30 million. The cost of capital is 12% and the tax rate is 25%.

If Amberfen Pharma uses the Internal Rate of Return (IRR) as its primary decision tool, which of the following is the most significant risk when comparing this project to a mutually exclusive project with a much larger scale?

  1. The IRR cannot be calculated if the project has only one sign change.
  2. The IRR assumes that cash flows are reinvested at the cost of capital.
  3. The IRR ignores the absolute dollar value added to the firm.

Sign up free to see the explanation and track your rank →

More CFA Level I Corporate Issuers practice

All Corporate Issuers questions · CFA Level I study guide · CFA Level I glossary · CFA Level I flashcards